Guí a OncoSur de infecc ione s en pac i ente s con tumor de órgano sól ido 98 > BIBLIOGRAFÍA 1. Baden LR, Swaminathan S, Angarone M, Blouin G, Camins BC, Casper C, et al. Prevention and Treatment of Cancer-Related Infections, Version 2.2016, NCCN Clinical Practice Guidelines in Oncology. J Natl Compr Canc Netw. 2016 Jul;14(7):882-913. DOI: 10.6004/jnccn.2016.0093 2. Centers for Disease Control and Prevention. Influenza antiviral medications: Summary for clinicians. Available from: https://www.cdc.gov/flu/professionals/antivirals/summary-clinicians.htm [Accessed: October 22, 2020]. 3. Uyeki TM, Bernstein HH, Bradley JS, Englund JA, File TM, Fry AM, et al. Clinical Practice Guidelines by the Infectious Diseases Society of America: 2018 Update on Diagnosis, Treatment, Chemoprophylaxis, and Institutional Outbreak Management of Seasonal Influenza. Clin Infect Dis. 2019 Mar 5;68(6):895-902. DOI: 10.1093/ cid/ciy874 4. Hwang JP,ArtzAS, SomerfieldMR. Hepatitis BVirus Screening for PatientsWith Cancer Before Therapy:American Society of Clinical Oncology Provisional Clinical Opinion Update. J Oncol Pract. 2015 Jul;11(4):e487-9. DOI: 10.1200/JOP.2015.004846 5. European Association for the Study of the Liver. EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection. J Hepatol. 2017 Aug;67(2):370-98. DOI: 10.1016/j.jhep.2017.03.021 6. Castellano G, Manzano ML. Tratamiento y profilaxis de la hepatitis B en pacientes inmunosuprimidos. Gastroenterol Hepatol. 2012;35(Espec Congr 1):1-19 7. AASLD-IDSA HCV Guidance Panel. HCV Guidance: Recommendations for Testing, Managing, and Treating Hepatitis C v2020.8. Available from: https://www.hcvguidelines.org/sites/default/files/full-guidance-pdf/AASLD-IDSA_HCVGuidance_August_27_2020.pdf 8. European Society of Medical Oncology. Cancer Patient Management During the COVID-19 Pandemic: supportive care strategies during the COVID-19 pandemic. Available from: https://www.esmo.org/guidelines/cancerpatient-management-during-the-covid-19-pandemic/supportive-care-in-the-covid-19-era — Tabla II — Antivirales de elección y posología Gripe - Quimioprofilaxis: 75 mg/día v.o. (1-2 semanas) - Tratamiento: 75 mg/12 h v.o. durante 5 días Hepatitis B (VHB) - Tenofovir TDF 300 mg/día; o tenofovir TAF 25 mg/día; o entecavir 0,5 mg/día (1 mg/día en pacientes previamente tratados con lamivudina); v.o. Hepatitis C (VHC) Consultar con especialista en enfermedades infecciosas/hepatología Herpes simple (VHS) - Infecciones mucocutáneas: aciclovir 400 mg/8 h; valaciclovir 1000 mg/12 h; famciclovir 500 mg/12 h vía oral (7-10 días) - Infecciones graves (o intolerancia oral): aciclovir 5 mg/kg/8 h i.v. Varicela-Zóster (VVZ) - Casos leves: aciclovir 800 mg x 5 tomas diarias; valaciclovir 1000 mg/8 h; famciclovir 500 mg/8 h, v.o. - Casos graves o diseminados: aciclovir 10 mg/kg/8 h i.v. (10-14 días) - Inmunoprofilaxis: VZIG 125 UI/10 kg, máximo 625 UI para peso > 40 kg Citomegalovirus (CMV) - De inicio: ganciclovir 5 mg/kg/12 h intravenoso; valganciclovir 900 mg/12 h v.o., o foscarnet 60 mg/8 h o 90 mg/12 h i.v. - Consultar con especialista en enfermedades infecciosas
RkJQdWJsaXNoZXIy OTI4NTYw